The role of interleukln-6 and C-reactive protein in gastric cancer;Rola interleukiny 6 oraz białka C-reaktywnego w raku zoła̧dka

Polski Merkuriusz Lekarski

Volumn 29, Issue 174, 2010, Pages 382-386

  Łukaszewicz Zaja̧c, Marta ^a   Mroczko, Barbara ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

C reactive protein (CRP); Gastric cancer; IL 6

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR MARKER;

BIOSYNTHESIS; CANCER INVASION; CANCER STAGING; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SECRETION; STOMACH TUMOR;

C-REACTIVE PROTEIN; HUMANS; INTERLEUKIN-6; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78951487136     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Ashizawa T., Okada R., Suzuki Y. i wsp.: Clinical significance of interieu-kin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer, 2005, 8, 124-131.
2. Balkwill F., Mantovani A.: Inflammation and cancer back to Virchow? Lancet, 2001, 357, 539-545.
3. Black S., Kushner I., Samols D.: C-reactive Protein. J. Biol. Chem., 2004, 279, 48487-48490.
4. Brenner H., Rothenbacher D., Arndt V.: Epidemiology of stomach cancer. Methods Mol. Biol., 2009, 472, 467-477.
5. Correa P., Schneider B.G.: Etiology of gastric cancer, what is new? Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1865-1868.
6. De Vita F., Romano C., Orditura M. i wsp.: Interieukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J. Interferon Cytokine Res., 2001, 21, 45-52.
7. Gaini S., Koldkjaer O.G., Pedersen C.: Procalcitonin, lipopolysacchari-de-binding protein, interieukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit. Care., 2006, 10, R53.
8. Goła̧b J., Jakóbisiak M., Lasek W. i wsp.: Immunologia. PWN, Warsza-wa, 2007.
9. Groblewska M., Mroczko B., Wereszczyńska-Siemia̧tkowska U. i wsp.: Serum interieukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin. Chem. Lab. Med., 2008, 46, 1423-1428.
10. Hara M., Matsuzaki Y., Shimuzu T. i wsp.: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res., 2007, 27, 3001-3004.
11. Huang S.P., Wu M.S., Wang H.P. i wsp. Correlation between serum levels of interieukin-6 and vascular endothelial growth factor in gastric carcinoma. J. Gastroenterol. Hepatol., 2002, 17, 1165-1169.
12. Hussain S.P., Harris C.C.: Inflammation and cancer an ancient link with novel potentials. Int. J. Cancer, 2007, 121, 2373-2380.
13. Ikeguchi M., Hatada T., Yamamoto M. i wsp.: Serum interieukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer, 2009, 12, 95-100.
14. Ilhan N., Ilhan Y., Akbulut H. i wsp.: C-reactive protein, procalcitonin, interieukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J. Gastroenterol., 2004, 10, 1115-1120.
15. Ito R., Yasui W., Kuniyasu H. i wsp.: Expression of interieukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn. J. Cancer Res., 1997, 88, 953-958. (Pubitemid 27507391)
16. Jang J.S., Choi S.R., Han S.Y. i wsp.: Predictive significance of serum IL-6, VEGF, and CRP in gastric adenoma and mucosal carcinoma before endoscopic submucosal dissection. Korean J. Gastroenterol., 2009, 54, 99-107.
17. Jurkowska G.: Choroby nowotworowe przewodu pokarmowego. Gastro-enterologia w praktyce, red., A. Gabryelewicz. PZWL, Warszawa, 2002, 251-297.
18. Kai H., Kitadai Y., Kodama M. i wsp.: Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res., 2005, 25, 709-713.
19. Kim D.K., Oh S.Y., Kwon H.C. i wsp.: Clinical significances of preoperative serum interieukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer, 2009, 9, 155.
20. Kishimoto T.: Interieukin-6: discovery of pleiotropic cytokine. Arthiritis Res. Ther., 2006, 8, S2.
21. Lazǎr D., Tǎban S., Sporea I. i wsp.: Gastric cancer correlation between clinicopathological factors and survival of patients. Rom. J. Morphol. Embryol., 2009, 50, 369-379.
22. Lee S.A., Choi S.R., Jang J.S. i wsp.: Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig. Dis. Sci. 2009, 12.
23. Liao W.C., Lin J.T., Wu C.Y. i wsp.: Serum interieukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res., 2008, 14, 428-434.
24. Matsuo K., Oka M., Murase K. i wsp.: Expression of interieukin 6 and its receptor in human gastric and colorectal cancers. J. Int. Med. Res., 2003, 31, 69-75.
25. McMillan D.C., Canna K., McArdle C.S.: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br. J. Surg., 2003, 90, 215-219.
26. Mroczko B., Groblewska M., Łukaszewicz-Zaja̧c M. i wsp.: Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin. Chem. Lab. Med., 2009, 47, 1133-1139.
27. Parkin D.M.: International variation. Oncogene, 2004, 23, 6329-6340.
28. Paul-PIetzer K.: Tocilizumab: blockade of interieukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today., 2006, 42, 559-576.
29. Ridker P.M., Hennekens C.H., Buring J.E. i wsp.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000, 342, 836-843.
30. Rosch T.: The new TNM classification in gastroenterology (1997). Endoscopy, 1998, 30, 643-649.
31. Rota S., Yildirim B., Kaleli B. i wsp.: C-reactive protein levels in non-obese pregnant women with gestational diabetes. Tohoku. J. Exp. Med., 2005, 206, 341-345.
32. Salgado R., Junius S., Benoy I. i wsp.: Circulating interieukin-6 predictors survival in patients with metastatic breast cancer. Int. J. Cancer, 2003, 103, 642-646.
33. Smith G.R., Missailidis S.: Cancer, inflammation and the AT1 and AT2 receptors. J. Inflamm (Lond)., 2004, 1, 3.
34. Thong-Ngam D., Tangkijvanich P., Lerknimitr R. i wsp.: Diagnostic role of serum interieukin-18 in gastric cancer patients. World J. Gastroenterol., 2006, 12, 4473-4477.
35. Thun M.J., Henley S.J., Patrono C.: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst., 2002, 94, 252-266.
36. Ueyama M., Maruyama I., Osame M.: Marked increase in plasma inter-leukin-6 in bum patients. J. Lab. Clin. Med., 1992, 120, 693-698.
37. Wang C.S., Sun C.F.: C-reactive protein and malignancy: clinico-patholo-gical association and therapeutic implication. Chang. Gung. Med. J., 2009, 32, 471-482.
38. Wu C.W., Wang S.R., Chao M.F. i wsp.: Serum interieukin-6 levels reflect disease status of gastric cancer. Am. J. Gastroenterol., 1996, 91, 1417-1422.